Related references
Note: Only part of the references are listed.The nocebo effect challenges the non-medical infliximab switch in practice
N. W. Boone et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Don Husereau et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2018)
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study
E. M. H. Schmitz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Federico Arguelles-Arias et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study
Xavier Roblin et al.
INFLAMMATORY BOWEL DISEASES (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel et al.
LANCET (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Long-Term Clinical Outcomes After Switching from RemicadeA® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Lisa J. T. Smits et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
L. Buer et al.
DIGESTIVE DISEASES (2017)
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
Mirthe E. van der Valk et al.
PLOS ONE (2016)
Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis
Sarah S. Thomas et al.
BIODRUGS (2015)
Infliximab-Related Infusion Reactions: Systematic Review
Lev Lichtenstein et al.
JOURNAL OF CROHNS & COLITIS (2015)
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Shomron Ben-Horin et al.
Expert Review of Gastroenterology & Hepatology (2015)
Prediction of Endoscopic Disease Activity in Ulcerative Colitis by Two Different Assays for Fecal Calprotectin
Vendel Kristensen et al.
JOURNAL OF CROHNS & COLITIS (2015)
Anaemia in inflammatory bowel disease: a population-based 10-year follow-up
M. L. Hoivik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Correlation Between the Crohn's Disease Activity and Harvey-Bradshaw Indices in Assessing Crohn's Disease Severity
Severine Vermeire et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
